{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:09:53Z","timestamp":1773079793318,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Targeted biologic therapies, especially monoclonal antibodies (mAbs) such as nivolumab and alemtuzumab, have revolutionized treatment for malignancies and autoimmune conditions but can cause rare immune-related adverse events (IRAEs), including orbitopathy. To date, only a handful of cases have described the treatment of thyroid eye disease secondary to mAbs, and even fewer have described how to treat refractory disease. Case Presentation: We are illustrating two cases in this report: a 73-year-old woman who developed thyroid eye disease (TED) after nivolumab therapy for melanoma, and a 36-year-old man who presented with TED following alemtuzumab treatment for multiple sclerosis. Both patients failed corticosteroid therapy but showed a significant improvement with teprotumumab, an anti-insulin-like growth factor (IGF)-1 receptor mAb. Conclusions: These cases highlight underrecognized orbital IRAEs linked to mAb therapy and demonstrate teprotumumab\u2019s potential as an effective option for steroid-refractory thyroid orbitopathy. Clinicians should maintain an awareness of orbital complications in patients receiving mAbs to enable prompt diagnosis and intervention, minimizing visual morbidity. Further studies are needed to clarify the pathogenesis of mAb-associated orbitopathy and to establish evidence-based treatment protocols for these rare but impactful complications.<\/jats:p>","DOI":"10.3390\/reports8040246","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:04:57Z","timestamp":1764151497000},"page":"246","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Reports of Teprotumumab as Treatment for Monoclonal Antibody-Induced Thyroid Orbitopathy"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4728-4410","authenticated-orcid":false,"given":"Jared","family":"Moon","sequence":"first","affiliation":[{"name":"Mitchel and Shannon Wong Eye Institute, Department of Ophthalmology, Dell Medical School at the University of Texas at Austin, Austin, TX 78712, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-1317","authenticated-orcid":false,"given":"Nicole","family":"Duncan","sequence":"additional","affiliation":[{"name":"Mitchel and Shannon Wong Eye Institute, Department of Ophthalmology, Dell Medical School at the University of Texas at Austin, Austin, TX 78712, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Yorio","sequence":"additional","affiliation":[{"name":"Texas Oncology, Austin, TX 78731, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-936X","authenticated-orcid":false,"given":"Ethan","family":"Meltzer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dell Medical School at the University of Texas at Austin, Austin, TX 78712, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4256-5793","authenticated-orcid":false,"given":"Moe H.","family":"Aung","sequence":"additional","affiliation":[{"name":"Mitchel and Shannon Wong Eye Institute, Department of Ophthalmology, Dell Medical School at the University of Texas at Austin, Austin, TX 78712, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000485742","article-title":"Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment","volume":"7","author":"Campredon","year":"2018","journal-title":"Eur. Thyroid J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tran, E., Hadi, A., Nair, G., Bursztyn, L.L., Fraser, J.A., and Ing, E.B. (2025). Incidence of alemtuzumab-induced thyroid-associated orbitopathy: A systematic review and meta-analysis. Ophthalmic Plast. Reconstr. Surg.","DOI":"10.1097\/IOP.0000000000003017"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: A systematic review","volume":"17","author":"Oweira","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint Inhibitor Immune Therapy: Systemic Indications and Ophthalmic Side Effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma","volume":"4","author":"Shoushtari","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis","volume":"30","author":"Bomze","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3109\/02713683.2014.993767","article-title":"Meta-analysis of Association Between the +49A\/G Polymorphism of Cytotoxic T-Lymphocyte Antigen-4 and Thyroid Associated Ophthalmopathy","volume":"40","author":"Wang","year":"2015","journal-title":"Curr. Eye Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, D.P., Chu, Y.C., Wen, Y.H., Lin, W.T., Hour, A.L., and Wang, W.T. (2019). Investigation of the Correlation between Graves\u2019 Ophthalmopathy and CTLA4 Gene Polymorphism. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111842"},{"key":"ref_14","first-page":"41","article-title":"CTLA-4 gene polymorphism associated with Graves\u2019 disease in a Caucasian population","volume":"80","author":"Yanagawa","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/thy.2005.15.239","article-title":"Immunoregulatory and Susceptibility Genes in Thyroid and Polyglandular Autoimmunity","volume":"15","author":"Dittmar","year":"2005","journal-title":"Thyroid"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-Induced Graves Disease From CTLA-4 Receptor Suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s00277-025-06344-8","article-title":"Alemtuzumab for haematological malignancies","volume":"104","author":"An","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: A review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"P2.199","DOI":"10.1212\/WNL.82.10_supplement.P2.199","article-title":"Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the CARE-MS Studies (P2.199)","volume":"82","author":"Twyman","year":"2014","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","article-title":"Alemtuzumab-induced thyroid events in multiple sclerosis: A systematic review and meta-analysis","volume":"43","author":"Scappaticcio","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e250007","DOI":"10.1530\/ETJ-25-0007","article-title":"Clinical management of alemtuzumab-induced autoimmune thyroid diseases: A narrative review","volume":"14","author":"Manso","year":"2025","journal-title":"Eur. Thyroid J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features","volume":"103","author":"Pariani","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41433-018-0282-1","article-title":"Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves\u2019 orbitopathy: A case series","volume":"33","author":"Roos","year":"2019","journal-title":"Eye"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/art.23122","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes","volume":"58","author":"Lorenzi","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/sj.onc.1210380","article-title":"Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Alinari","year":"2007","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/art.1780381110","article-title":"Campath-1h, a humanized monoclonal antibody, in refractory rheumatoid arthritis","volume":"38","author":"Weinblatt","year":"1995","journal-title":"Arthritis Rheum."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/IOP.0000000000002367","article-title":"Alemtuzumab-Induced Thyroid Eye Disease: A Comprehensive Case Series and Review of the Literature","volume":"39","author":"Nirmalan","year":"2023","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00415-023-11995-6","article-title":"Alemtuzumab induces severe orbitopathy in relapsing\u2013remitting multiple sclerosis","volume":"271","author":"Ruiz","year":"2024","journal-title":"J. Neurol."},{"key":"ref_32","first-page":"ep959","article-title":"Graves\u2019 orbitopathy caused by alemtuzumab: A case series","volume":"81","author":"Mendez","year":"2022","journal-title":"Endocr. Abstr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the Treatment of Active Thyroid Eye Disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/246\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:55:58Z","timestamp":1764154558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["reports8040246"],"URL":"https:\/\/doi.org\/10.3390\/reports8040246","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}